Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

4(57.1%)

Phase 1

3(42.9%)

7Total

N/A(4)

Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT04446351Phase 1Active Not Recruiting

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Role: collaborator

NCT06993142Not ApplicableNot Yet Recruiting

Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage

Role: collaborator

NCT06193252Not ApplicableRecruiting

Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands

Role: collaborator

NCT05028894Completed

23andMe IPF Research Study

Role: lead

NCT06290388Phase 1Terminated

Study of 23ME-01473 in Patients With Advanced Solid Malignancies

Role: lead

NCT05199272Phase 1Active Not Recruiting

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Role: lead

NCT03446079Not ApplicableCompleted

Relationship of Skin Related SNP to Topical Skin Care Product

Role: collaborator

NCT01351467Completed

Web-based Genetic Research on Parkinson's Disease

Role: lead

NCT03400696Not ApplicableCompleted

Web-based Weight Loss Intervention

Role: lead

NCT02530944Completed

Web-based Genetic Research on Lupus

Role: lead

NCT01598597Completed

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Role: collaborator

All 11 trials loaded